Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors

Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Rosomidnar (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors ProNAi Therapeutics
  • Most Recent Events

    • 09 Nov 2012 Results were presented at the the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, according to a ProNai Therapeutics media release.
    • 09 Nov 2012 Status changed from recruiting to completed, as reported in a ProNAi Therapeutics media release.
    • 04 Jun 2012 The ten planned dose cohorts have been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top